<DOC>
	<DOCNO>NCT01684878</DOCNO>
	<brief_summary>This two-part , multicenter study evaluate safety , tolerability efficacy pertuzumab combination standard chemotherapy woman recurrent platinum-resistant epithelial ovarian cancer . In non-randomized Part 1 safety run-in , participant receive pertuzumab plus either topotecan paclitaxel . In randomized , double-blind Part 2 study , participant receive either pertuzumab placebo combination chemotherapy ( topotecan , paclitaxel , gemcitabine ) .</brief_summary>
	<brief_title>Pertuzumab Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 ( HER3 ) Messenger Ribonucleic Acid ( mRNA ) Epithelial Ovarian Cancer ( PENELOPE )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histologically cytologically confirm epithelial ovarian , primary peritoneal , and/or fallopian tube cancer platinumresistant refractory Low Human epidermal growth factor receptor ( HER ) 3 messenger ribonucleic acid ( mRNA ) expression At least one measurable and/or nonmeasurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) version ( V ) 1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Left ventricular ejection fraction ( LVEF ) great equal ( &gt; /= ) 50 percent ( % ) Negative serum pregnancy test woman childbearing potential Women childbearing potential must agree use effective contraception define protocol least 6 month post study treatment Nonepithelial tumor Ovarian tumor low malignant potential ( borderline tumor ) History malignancy prognostic relevance within last 5 year , except carcinoma situ cervix basal cell carcinoma , tumor negligible risk metastasis death , adequately control basalcell carcinoma squamous cell carcinoma skin carcinoma situ cervix carcinoma situ breast Previous treatment 2 chemotherapy regimens Any prior radiotherapy pelvis abdomen History evidence physical/neurological examination central nervous system disease unrelated cancer ( uncontrolled seizure ) , unless adequately treat standard medical therapy Preexisting peripheral neuropathy &gt; /= common toxicity criterion ( CTC ) grade 2 ( applicable paclitaxel cohort ) Inadequate organ function Uncontrolled hypertension clinically significant cardiovascular disease Current know infection human immunodeficiency virus ( HIV ) active infection hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) Current chronic daily treatment corticosteroid ( &gt; /= 10 mg per day methylprednisolone equivalent ) , exclude inhaled steroid History receive investigational treatment within 28 day prior first study drug administration For Part 2 trial : prior enrollment Part 1 trial Concurrent participation therapeutic clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>